Go Back To Menu
Close
- Mailing Form
-
Medical Report*
-
Go Back To Menu
Systemic sclerosis (SSc) is a connective tissue disease characterized by skin and internal organ fibrosis, belonging to the category of autoimmune diseases. Patients often present with skin thickening, vascular abnormalities, and multi-organ damage. The exact cause is not fully understood and may be related to genetic, environmental, and abnormal immune responses. Early recognition and intervention can delay disease progression.
Europe and North America
The prevalence of systemic sclerosis in Europe and North America is about 50–300 cases per million, with a significantly higher proportion of female patients compared to males (about 4:1). In developed countries, the diagnosis rate is higher, and patients can receive immunosuppressive therapy and complication management earlier, resulting in survival rates superior to the global average.
Southeast Asia
Data on patients in Southeast Asia are limited, but studies show that prevalence is lower than in Europe and North America. However, due to limited medical resources in some areas, many patients are not diagnosed until the middle or late stages of the disease, often accompanied by severe pulmonary hypertension or renal crisis, leading to relatively high mortality rates.
1. Multi-organ fibrosis and dysfunction
Systemic sclerosis can affect multiple organs such as the lungs, heart, kidneys, and gastrointestinal tract, leading to extensive fibrosis and irreversible functional damage. For example, interstitial lung disease can cause breathing difficulties, and renal crisis can lead to acute renal failure, posing a serious threat to patients’ lives.
2. Immune and vascular complications
In addition to fibrosis, patients often have vascular dysfunction such as Raynaud’s phenomenon, microvascular lesions, and persistent immune activation. These changes increase the risk of cardiovascular events and may trigger chronic inflammatory responses, accelerating organ function deterioration and affecting quality of life and lifespan.
Immune reconstruction cell therapy reshapes the patient’s immune system, reducing fibrosis and inflammation caused by abnormal immune responses. The treatment uses the synergistic effects of various immune cells to inhibit pathogenic immune cell activity, restore immune balance, and promote repair and regeneration of damaged tissues, providing new treatment opportunities for patients in middle and late stages.
1. Reversing fibrosis progression
Inhibits excessive fibroblast proliferation and collagen deposition, reducing the degree of skin and internal organ sclerosis.
2. Improving microcirculation and vascular function
Regulates immune responses to reduce vascular inflammation, improve blood flow and oxygen supply, and alleviate Raynaud’s phenomenon.
3. Enhancing immune regulation
Restores immune tolerance, reduces disease recurrence and complication risks, and improves long-term prognosis and quality of life.
In actual treatment, traditional therapy often faces problems such as immune dysfunction, increased infection risk, and slow recovery. To better support patients, enhance tolerance, and improve quality of life, it is necessary to scientifically design phased immune reconstruction plans tailored to different treatment cycles.
● Short-term plan: Rapidly enhance immunity through immune cell reinfusion to improve treatment effectiveness.
● Mid-term plan: Reduce side effects of traditional therapies, promote recovery, and ensure completion of standardized courses.
● Long-term plan: Improve overall immunity through immune cell reconstruction, gut immune reconstruction, elemental immune reconstruction, and immune nutrition reconstruction, thereby improving quality of life and extending survival.
1. Immunosuppressants
Such as cyclophosphamide and azathioprine, which can suppress overactive immune responses and delay organ damage.
2. Glucocorticoids
Used to control inflammation and acute exacerbations, but long-term use requires attention to side effects such as osteoporosis and infection risks.
3. Vasodilators
Such as calcium channel blockers and prostacyclin analogues, used to improve Raynaud’s phenomenon and pulmonary hypertension.
4. Antifibrotic drugs
Such as pirfenidone and nintedanib, which can slow the progression of interstitial lung disease.
5. Symptomatic and supportive treatment
Including prokinetic agents and antacids to relieve gastrointestinal symptoms and improve nutritional absorption.
Systemic sclerosis is a highly harmful autoimmune disease that, if not treated in time, can lead to severe organ damage and disability. Early intervention and comprehensive management are crucial for improving prognosis. Experts at United Life International Medical Center state that combining emerging immune reconstruction cell therapy with traditional drugs and supportive therapies is expected to bring better treatment outcomes and quality of life for patients.
